Thermo Fisher Scientific, a global leader in serving science, is excited to announce the signing of a Memorandum of Understanding (MoU) with BioCell Innovations Pte Ltd, a pioneer in lentivirus CAR construct development. This strategic partnership aims to optimize a closed process for the clinical manufacturing of lentiviral-based immunotherapies within the Asia-Pacific region.

By combining BioCell Innovations' expertise in the development of lentiviral CAR constructs with Thermo Fisher Scientific's advanced solutions for closed, modular cell processing, the collaboration seeks to streamline the transition from research to clinical and commercial manufacturing for developers. This initiative is designed to accelerate the development pipelines for CAR-T cell therapies, ultimately enhancing the availability and effectiveness of these cutting-edge treatments.

The collaboration between Thermo Fisher Scientific and BioCell Innovations underscores their shared commitment to advancing medical science and improving patient outcomes. As the demand for CAR-T cell therapies continues to grow, this partnership is poised to play a crucial role in meeting the needs of the healthcare industry within the Asia-Pacific region.